In The News

The Myeloma Crowd Multiple Myeloma Research, Funding, News, Tips and Help

  • We Love Our Myeloma Coaches! Glori & Terry Traeder’s Story
    by Erika Johnson on November 8, 2019 at 4:04 am

    Find or Become a Myeloma Coach   Written by Glori Traeder   We just finished Terry’s 100 day post stem cell transplant appointment with Dr. Jacob Laubach at Dana Farber Cancer Institute. He has had a great recovery, he is feeling very well and has “pristine” lab results. Now on to maintenance.   After […]

  • Myeloma Crowd Round Table Expert Videos: Seattle — September 28, 2019
    by Erika Johnson on November 8, 2019 at 3:53 am

    On September 28, 2019, a Myeloma Crowd Round Table meeting was held in Seattle, Washington at the Fred Hutchinson Cancer Research Center featuring six myeloma experts, including: Dr. Edward Libby, Seattle Cancer Care Alliance, Seattle, WA Dr. Leona Holmberg, Seattle Cancer Care Alliance, Seattle, WA Dr. Faith Davies, NYU Perlmutter Cancer Center, New York, NY […]

  • Full Show: Weighing Cancer Cells for Personalized Myeloma Therapy with Clifford Reid, PhD, Travera
    by Jenny A on November 8, 2019 at 3:40 am

    Clifford Reid, PhD Travera  Interview Date: October 23, 2019 Thanks to our episode sponsor Summary Can you tell how well a myeloma treatment might work on your personal tumor by weighing the cancer cells? Clifford Reid, PhD and CEO of Travera shares a new approach to “personalized medicine” in multiple myeloma. Cancer cells […]

  • Lenalidomide Can Delay Bone and Organ Damage for Smoldering Myeloma Patients
    by Jenny A on November 1, 2019 at 6:13 pm

    In the largest ever study of smoldering myeloma patients from 13 major myeloma facilities, lenalidomide was found to delay disease progression, and helped prevent bone damage and end organ damage. The study was run by the Eastern Cooperative Oncology Group and funded by the National Cancer Institute. The study included 182 intermediate or high risk […]

  • First Patient Dosed with Off-The-Shelf Donor CAR T Cell Therapy Targeting CS1
    by Jenny A on November 1, 2019 at 4:54 am

    A new CAR T treatment has been delivered to the first myeloma patient, using an off-the-shelf approach with donor T cells aimed at a new target, CS1. Most CAR T cell therapies in today’s multiple myeloma clinical trials are “autologous,” meaning they use the patient’s own T cells. Many CAR T cell therapies in Phase […]

Myeloma Research News The Web’s Daily Resource for Myeloma Research News

  • Nektar Launches First-in-Human Trial Testing NKTR-255 in Myeloma, Non-Hodgkin’s Lymphoma
    by Alejandra Viviescas, PhD. on November 11, 2019 at 2:57 pm

    Nektar Therapeutics is launching a first-in-human Phase 1 clinical trial to assess the safety and efficacy of NKTR-255 in adults with relapsed or refractory multiple myeloma and non-Hodgkin’s lymphoma. “We are excited to launch the first-in-human clinical study of NKTR-255, which has shown promising and substantial anti-tumor activity in our preclinical studies,” Wei Lin, MD, the company’s The post Nektar Launches First-in-Human Trial Testing NKTR-255 in Myeloma, Non-Hodgkin’s Lymphoma appeared first on Myeloma Research News.

  • Bispecific Antibody in Phase 1 Multiple Myeloma Trial Named Orphan Drug by FDA, Teneobio Announces
    by Patricia Inacio, PhD on November 8, 2019 at 1:26 pm

    The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Teneobio‘s bispecific antibody TNB-383B as a possible treatment of multiple myeloma. Orphan drug designation provides Teneobio with benefits, including financial incentives for therapy development and commercialization, should it be approved. It also provides U.S. market exclusivity for seven years upon approval, FDA support for clinical The post Bispecific Antibody in Phase 1 Multiple Myeloma Trial Named Orphan Drug by FDA, Teneobio Announces appeared first on Myeloma Research News.

  • Use of Darzalez and Xpovio Expected to Increase Due to New Approvals, Spherix Survey Shows
    by Marta Figueiredo on November 6, 2019 at 2:15 pm

    U.S. blood cancer specialists are aware of recent approvals for multiple myeloma patients and expect to increase their use of Darzalex (daratumumab) as first-line combination therapy, as well as Xpovio (selinexor) as a fifth-line combination therapy, according to a survey conducted by market research firm Spherix Global Insights. The data also highlighted a general optimism regarding the The post Use of Darzalez and Xpovio Expected to Increase Due to New Approvals, Spherix Survey Shows appeared first on Myeloma Research News.

  • Darzalex Combo Approved in Canada for Newly Diagnosed Myeloma Patients Ineligible for Transplant
    by Alejandra Viviescas, PhD. on November 4, 2019 at 1:34 pm

    Health Canada has approved Darzalex (daratumumab), in combination with standard Revlimid (lenalidomide) and dexamethasone, for people newly diagnosed with multiple myeloma who are not eligible for an autologous stem cell transplant. Under priority review, the approval was based on data from the Phase 3 MAIA trial (NCT02252172), in which Darzalex cut the risk of disease progression or The post Darzalex Combo Approved in Canada for Newly Diagnosed Myeloma Patients Ineligible for Transplant appeared first on Myeloma Research News.

  • Next Up for ‘Moving Mountains for Multiple Myeloma’ — Patagonia
    by Mary Chapman on November 1, 2019 at 3:30 pm

    With the goal of encouraging the multiple myeloma community while raising money to advance treatments, Moving Mountains for Multiple Myeloma (MM4MM) is gearing up for its next expedition — Patagonia. The Nov. 9–19 excursion will take participants across the picturesque, but often-rugged, terrain of the region at the southern end of South America that’s shared by Argentina and Chile. The post Next Up for ‘Moving Mountains for Multiple Myeloma’ — Patagonia appeared first on Myeloma Research News.

Myeloma Research News The Web’s Daily Resource for Myeloma Research News

  • Nektar Launches First-in-Human Trial Testing NKTR-255 in Myeloma, Non-Hodgkin’s Lymphoma
    by Alejandra Viviescas, PhD. on November 11, 2019 at 2:57 pm

    Nektar Therapeutics is launching a first-in-human Phase 1 clinical trial to assess the safety and efficacy of NKTR-255 in adults with relapsed or refractory multiple myeloma and non-Hodgkin’s lymphoma. “We are excited to launch the first-in-human clinical study of NKTR-255, which has shown promising and substantial anti-tumor activity in our preclinical studies,” Wei Lin, MD, the company’s The post Nektar Launches First-in-Human Trial Testing NKTR-255 in Myeloma, Non-Hodgkin’s Lymphoma appeared first on Myeloma Research News.

  • Bispecific Antibody in Phase 1 Multiple Myeloma Trial Named Orphan Drug by FDA, Teneobio Announces
    by Patricia Inacio, PhD on November 8, 2019 at 1:26 pm

    The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Teneobio‘s bispecific antibody TNB-383B as a possible treatment of multiple myeloma. Orphan drug designation provides Teneobio with benefits, including financial incentives for therapy development and commercialization, should it be approved. It also provides U.S. market exclusivity for seven years upon approval, FDA support for clinical The post Bispecific Antibody in Phase 1 Multiple Myeloma Trial Named Orphan Drug by FDA, Teneobio Announces appeared first on Myeloma Research News.

  • Use of Darzalez and Xpovio Expected to Increase Due to New Approvals, Spherix Survey Shows
    by Marta Figueiredo on November 6, 2019 at 2:15 pm

    U.S. blood cancer specialists are aware of recent approvals for multiple myeloma patients and expect to increase their use of Darzalex (daratumumab) as first-line combination therapy, as well as Xpovio (selinexor) as a fifth-line combination therapy, according to a survey conducted by market research firm Spherix Global Insights. The data also highlighted a general optimism regarding the The post Use of Darzalez and Xpovio Expected to Increase Due to New Approvals, Spherix Survey Shows appeared first on Myeloma Research News.

  • Darzalex Combo Approved in Canada for Newly Diagnosed Myeloma Patients Ineligible for Transplant
    by Alejandra Viviescas, PhD. on November 4, 2019 at 1:34 pm

    Health Canada has approved Darzalex (daratumumab), in combination with standard Revlimid (lenalidomide) and dexamethasone, for people newly diagnosed with multiple myeloma who are not eligible for an autologous stem cell transplant. Under priority review, the approval was based on data from the Phase 3 MAIA trial (NCT02252172), in which Darzalex cut the risk of disease progression or The post Darzalex Combo Approved in Canada for Newly Diagnosed Myeloma Patients Ineligible for Transplant appeared first on Myeloma Research News.

  • Next Up for ‘Moving Mountains for Multiple Myeloma’ — Patagonia
    by Mary Chapman on November 1, 2019 at 3:30 pm

    With the goal of encouraging the multiple myeloma community while raising money to advance treatments, Moving Mountains for Multiple Myeloma (MM4MM) is gearing up for its next expedition — Patagonia. The Nov. 9–19 excursion will take participants across the picturesque, but often-rugged, terrain of the region at the southern end of South America that’s shared by Argentina and Chile. The post Next Up for ‘Moving Mountains for Multiple Myeloma’ — Patagonia appeared first on Myeloma Research News.